AU4975090A – Mitomycin c derivatized with a hapten
– Google Patents
AU4975090A – Mitomycin c derivatized with a hapten
– Google Patents
Mitomycin c derivatized with a hapten
Info
Publication number
AU4975090A
AU4975090A
AU49750/90A
AU4975090A
AU4975090A
AU 4975090 A
AU4975090 A
AU 4975090A
AU 49750/90 A
AU49750/90 A
AU 49750/90A
AU 4975090 A
AU4975090 A
AU 4975090A
AU 4975090 A
AU4975090 A
AU 4975090A
Authority
AU
Australia
Prior art keywords
hapten
mitomycin
derivatized
diagnostic
modified
Prior art date
1985-09-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU49750/90A
Other versions
AU629903B2
(en
Inventor
Richard M. Bartholomew
Gary S. David
James M. Frincke
Damon L. Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1985-09-12
Filing date
1990-02-13
Publication date
1990-11-29
1990-02-13
Application filed by Hybritech Inc
filed
Critical
Hybritech Inc
1990-11-29
Publication of AU4975090A
publication
Critical
patent/AU4975090A/en
1992-10-15
Application granted
granted
Critical
1992-10-15
Publication of AU629903B2
publication
Critical
patent/AU629903B2/en
2006-09-12
Anticipated expiration
legal-status
Critical
Status
Ceased
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K49/00—Preparations for testing in vivo
A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
A61K51/04—Organic compounds
A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
A61K51/04—Organic compounds
A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
A61K51/04—Organic compounds
A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
A61K51/04—Organic compounds
A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K16/3007—Carcino-embryonic Antigens
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/46—Hybrid immunoglobulins
C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
G—PHYSICS
G01—MEASURING; TESTING
G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 – G01N31/00
G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
G01N33/531—Production of immunochemical test materials
G—PHYSICS
G01—MEASURING; TESTING
G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 – G01N31/00
G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K39/00—Medicinal preparations containing antigens or antibodies
A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K2123/00—Preparations for testing in vivo
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K38/00—Medicinal preparations containing peptides
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2317/00—Immunoglobulins specific features
C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2317/00—Immunoglobulins specific features
C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
C07K2317/54—F(ab’)2
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2317/00—Immunoglobulins specific features
C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
C07K2317/55—Fab or Fab’
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2319/00—Fusion polypeptide
Abstract
Antibody complexes comprising hapten-modified diagnostic or therapeutic agents and anti-hapten antibodies are disclosed. Administration of hapten-modified agents, complexed with suitable anti-hapten antibodies, extends the serum half-life and permits an increased concentration of such diagnostic or therapeutic agents at in vivo target sites.
AU49750/90A
1985-09-12
1990-02-13
Mitomycin c derivatized with a hapten
Ceased
AU629903B2
(en)
Applications Claiming Priority (2)
Application Number
Priority Date
Filing Date
Title
US77546185A
1985-09-12
1985-09-12
US775461
1985-09-12
Related Parent Applications (1)
Application Number
Title
Priority Date
Filing Date
AU62646/86A
Division
AU597903B2
(en)
1985-09-12
1986-09-12
Antibody complexes of hapten-modified diagnostic or therapeutic agents
Publications (2)
Publication Number
Publication Date
AU4975090A
true
AU4975090A
(en)
1990-11-29
AU629903B2
AU629903B2
(en)
1992-10-15
Family
ID=25104504
Family Applications (2)
Application Number
Title
Priority Date
Filing Date
AU62646/86A
Ceased
AU597903B2
(en)
1985-09-12
1986-09-12
Antibody complexes of hapten-modified diagnostic or therapeutic agents
AU49750/90A
Ceased
AU629903B2
(en)
1985-09-12
1990-02-13
Mitomycin c derivatized with a hapten
Family Applications Before (1)
Application Number
Title
Priority Date
Filing Date
AU62646/86A
Ceased
AU597903B2
(en)
1985-09-12
1986-09-12
Antibody complexes of hapten-modified diagnostic or therapeutic agents
Country Status (8)
Country
Link
EP
(1)
EP0217577B1
(en)
JP
(1)
JPS6270377A
(en)
AT
(1)
ATE77056T1
(en)
AU
(2)
AU597903B2
(en)
CA
(1)
CA1282069C
(en)
DE
(1)
DE3685625T2
(en)
IL
(2)
IL80020A0
(en)
NZ
(1)
NZ217570A
(en)
Families Citing this family (48)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US5700466A
(en)
*
1981-09-08
1997-12-23
The Rockefeller University
Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US5543145A
(en)
*
1984-09-17
1996-08-06
Baxter International, Inc.
Pharmaceutical composition and method for the suppression of factor VIII inhibitor production
FR2604092B1
(en)
*
1986-09-19
1990-04-13
Immunotech Sa
IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO
DE68916052T2
(en)
*
1988-02-03
1994-11-10
Hybritech Inc
Modified haptens, useful as an image-forming agent and as a medicament.
US5322678A
(en)
*
1988-02-17
1994-06-21
Neorx Corporation
Alteration of pharmacokinetics of proteins by charge modification
US5635180A
(en)
*
1988-02-17
1997-06-03
Neorx Corporation
Alteration of pharmacokinetics of proteins by charge modification
US5851527A
(en)
*
1988-04-18
1998-12-22
Immunomedics, Inc.
Method for antibody targeting of therapeutic agents
FR2652004B1
(en)
*
1989-09-21
1994-10-28
Immunotech Partners
NOVEL HYDROPHILIC DERIVATIVES, APPLICATION TO DIAGNOSIS AND THERAPEUTICS, DIAGNOSTIC OR THERAPEUTIC KITS AND IMMUNOLOGICAL REAGENTS.
EP0505357B1
(en)
*
1989-12-11
1999-03-10
Immunomedics, Inc.
Method for antibody targeting of diagnostic or therapeutic agents
CA2015515C
(en)
1990-01-03
1999-12-07
Jean-Marie Saint-Remy
Pharmaceutical compositions containing antigen-antibody complexes and uses therefor
US5273743A
(en)
*
1990-03-09
1993-12-28
Hybritech Incorporated
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
WO1992017215A1
(en)
1990-03-28
1992-10-15
Nycomed Salutar, Inc.
Contrast media
GB9006977D0
(en)
1990-03-28
1990-05-23
Nycomed As
Compositions
AU2541592A
(en)
*
1991-08-01
1993-03-02
Hybritech Incorporated
Improvements in or relating to modified haptens useful as imaging and therapeutic agents
CA2157785A1
(en)
*
1993-03-19
1994-09-29
Immunex Corporation
Pharmaceutical compositions comprising soluble interleukin-4 receptor and interleukin-4
GB9314623D0
(en)
1993-07-14
1993-08-25
Nordion Int Inc
Localization and therapy with agents directed against prostate specific antigen in breast cancer
US5541110A
(en)
1994-05-17
1996-07-30
Bristol-Myers Squibb
Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
EP0805815B1
(en)
*
1995-01-26
2002-04-10
Nycomed Imaging A/S
Use of bismuth compounds for the manufacture of medicaments for the treatment of gastric disorders caused by Helicobacter pylori
GB9501560D0
(en)
1995-01-26
1995-03-15
Nycomed Imaging As
Contrast agents
DE19505960A1
(en)
1995-02-21
1996-08-22
Deutsches Krebsforsch
Conjugate for the individual dosage of drugs
WO1998008875A1
(en)
*
1996-08-28
1998-03-05
Viva Diagnostika Diagnostische Produkte Gmbh
Novel combination preparations and their use in immunodiagnosis and immunotherapy
US6869606B1
(en)
1999-02-22
2005-03-22
Millennium Pharmaceuticals, Inc.
Biotinylated-chemokine antibody complexes
AU5697001A
(en)
*
2000-03-31
2001-10-15
Purdue Research Foundation
Method of treatment using ligand-immunogen conjugates
US20020132274A1
(en)
2001-01-17
2002-09-19
Nevalainen Marja T.
Diagnostic and monitorings methods for cancer
CA2464472C
(en)
2001-10-22
2014-01-07
The Scripps Research Institute
Antibody targeting compounds
US7659241B2
(en)
2002-07-31
2010-02-09
Seattle Genetics, Inc.
Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
SG10201701737XA
(en)
2003-11-06
2017-04-27
Seattle Genetics Inc
Monomethylvaline compounds capable of conjugation to ligands
JP4918476B2
(en)
2004-03-16
2012-04-18
テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション
Substituted phenoxy- and phenylthio-derivatives for treating proliferative diseases
JP2008519863A
(en)
2004-11-12
2008-06-12
シアトル ジェネティクス インコーポレイティッド
Auristatin having an aminobenzoic acid unit at the N-terminus
US8067546B2
(en)
2005-04-19
2011-11-29
Seattle Genetics, Inc.
Humanized anti-CD70 binding agents and uses thereof
ES2908458T3
(en)
2005-07-18
2022-04-29
Seagen Inc
Beta-glucuronide drug-linker conjugates
US8168164B2
(en)
2006-02-03
2012-05-01
Purdue Research Foundation
Targeted conjugates and radiation
ES2523915T5
(en)
2006-12-01
2022-05-26
Seagen Inc
Variant Target Binding Agents and Uses Thereof
ES2374330T3
(en)
2007-01-22
2012-02-15
Genentech, Inc.
PRECIPITATION WITH POLYELECTROLYTE AND PURIFICATION OF ANTIBODIES.
CA2723197C
(en)
2008-05-02
2017-09-19
Seattle Genetics, Inc.
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1
(en)
2010-04-22
2011-10-27
Boston Medical Center Corporation
Compositions and methods for targeting and delivering therapeutics into cells
US9353150B2
(en)
2012-12-04
2016-05-31
Massachusetts Institute Of Technology
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US9522876B2
(en)
2013-03-15
2016-12-20
Zymeworks Inc.
Cytotoxic and anti-mitotic compounds, and methods of using the same
ES2916722T3
(en)
2013-12-27
2022-07-05
Zymeworks Inc
Sulfonamide-containing linkage systems for drug conjugates
EP3194421B1
(en)
2014-09-17
2021-11-03
Zymeworks Inc.
Cytotoxic and anti-mitotic compounds, and methods of using the same
US10618935B2
(en)
2015-11-03
2020-04-14
Industrial Technology Research Institute
Antibody-drug conjugate (ADC) and method for forming the same
US10918627B2
(en)
2016-05-11
2021-02-16
Massachusetts Institute Of Technology
Convergent and enantioselective total synthesis of Communesin analogs
US10640508B2
(en)
2017-10-13
2020-05-05
Massachusetts Institute Of Technology
Diazene directed modular synthesis of compounds with quaternary carbon centers
CN114173824A
(en)
2019-05-10
2022-03-11
武田药品工业株式会社
Antibody drug conjugates
US11535634B2
(en)
2019-06-05
2022-12-27
Massachusetts Institute Of Technology
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
TW202138388A
(en)
2019-12-30
2021-10-16
美商西根公司
Methods of treating cancer with nonfucosylated anti-cd70 antibodies
WO2022097117A1
(en)
2020-11-09
2022-05-12
Takeda Pharmaceutical Company Ltd.
Antibody drug conjugates
WO2023278377A1
(en)
2021-06-29
2023-01-05
Seagen Inc.
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
Family Cites Families (6)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
NZ206932A
(en)
*
1983-02-07
1987-08-31
University Patents Inc
Certain 6-(heterocyclyl or amino) mitosanes and pharmaceutical compositions
US4485086A
(en)
*
1983-04-11
1984-11-27
Wong Dennis W
Radiolabeled tumor imaging agent and method of preparation
US4642352A
(en)
*
1983-12-23
1987-02-10
Bristol-Myers Company
Acylamino mitosanes
US4888341A
(en)
*
1984-09-04
1989-12-19
University Patents, Inc.
6-substituted mitomycin analogs
AU609387B2
(en)
*
1986-03-26
1991-05-02
Syntex (U.S.A.) Inc.
Liquid single reagent for assays
IL83419A0
(en)
*
1986-09-15
1988-01-31
Westinghouse Electric Corp
Antibodies reactive with chlorinated phenols,their preparation and their use
1986
1986-09-08
CA
CA000517663A
patent/CA1282069C/en
not_active
Expired – Fee Related
1986-09-12
IL
IL80020A
patent/IL80020A0/en
not_active
IP Right Cessation
1986-09-12
AU
AU62646/86A
patent/AU597903B2/en
not_active
Ceased
1986-09-12
EP
EP86307031A
patent/EP0217577B1/en
not_active
Expired – Lifetime
1986-09-12
NZ
NZ217570A
patent/NZ217570A/en
unknown
1986-09-12
IL
IL97411A
patent/IL97411A/en
unknown
1986-09-12
JP
JP61216963A
patent/JPS6270377A/en
active
Pending
1986-09-12
DE
DE8686307031T
patent/DE3685625T2/en
not_active
Expired – Fee Related
1986-09-12
AT
AT86307031T
patent/ATE77056T1/en
not_active
IP Right Cessation
1990
1990-02-13
AU
AU49750/90A
patent/AU629903B2/en
not_active
Ceased
Also Published As
Publication number
Publication date
AU6264686A
(en)
1987-03-19
NZ217570A
(en)
1989-04-26
JPS6270377A
(en)
1987-03-31
EP0217577A2
(en)
1987-04-08
EP0217577A3
(en)
1987-09-09
EP0217577B1
(en)
1992-06-10
AU629903B2
(en)
1992-10-15
CA1282069C
(en)
1991-03-26
DE3685625D1
(en)
1992-07-16
ATE77056T1
(en)
1992-06-15
IL80020A0
(en)
1986-12-31
AU597903B2
(en)
1990-06-14
DE3685625T2
(en)
1993-01-28
IL97411A
(en)
1993-01-14
Similar Documents
Publication
Publication Date
Title
AU629903B2
(en)
1992-10-15
Mitomycin c derivatized with a hapten
DE3751574D1
(en)
1995-11-30
DIAGNOSTIC AND MEDICINE ANTIBODY CONJUGATES.
AU7366687A
(en)
1987-12-03
Coupling agents for radiolabeling proteins
CA1024868A
(en)
1978-01-24
Reagent and method for determining leukocytes and hemoglobin in the blood
AU1768388A
(en)
1989-02-23
Ultrasonic air-in-line detector
AU7865687A
(en)
1988-04-21
Affinity enhancement system
AU3035189A
(en)
1989-08-25
Ultrasonic contrast agents, process for producing them and their use as diagnostic and therapeutic agents
ES2013978A4
(en)
1990-06-16
MACROCYCLIC BIFUNCTIONAL IONIC LINK COMPOUNDS, COMPLEXES OF THEM AND THEIR CONJUGATED ANTIBODIES
GB9824632D0
(en)
1999-01-06
Biological compounds
AU529210B3
(en)
1983-04-14
Monoclonal antibody in occult blood diagnosis
DE68912334D1
(en)
1994-02-24
IMMUNOCONJUGATES FOR CANCER DIAGNOSIS AND THERAPY.
AU6785987A
(en)
1987-07-30
Selecting and testing antibodies for cancer therapy
CA2182289A1
(en)
1995-08-03
Immuno-stimulatory monoclonal antibodies
DK556689A
(en)
1990-05-14
ANTIBODY CONJUGATES, PROCEDURES FOR PREPARING THEM AND PHARMACEUTICAL AGENTS CONTAINING THESE
AU4953693A
(en)
1994-03-15
Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
AU616667B2
(en)
1991-11-07
Monoclonal antibodies against e7 protein of human type 16 papillomavirus, a process for their preparation, and their use
CA2139518A1
(en)
1994-01-20
Antigenic regions of tlp complexes and antibodies against the same
GR3007000T3
(en)
1993-06-30
IL95407A0
(en)
1991-06-30
Reagent for the detection of fibrinolytic activity
DE3790139D2
(en)
1988-08-25
Antiparatypical antibodies, their use for detecting and treating auto-immune diseases
EP0444787A3
(en)
1992-02-05
Monoclonal antibodies against non-a 1c glycated hemoglobin
EP0214281A4
(en)
1989-03-16
Protein absorption enhancing agents.
EP0261225A4
(en)
1989-10-27
Lectin complex and method and probe for making same.
ES2002578A6
(en)
1988-08-16
A process for the preparation of diagnostic reagents.
KR860008779A
(en)
1986-12-18
Method for producing antibody forming compound
None